Literature DB >> 14705967

Studies on regulation of IGF (insulin-like growth factor)-binding protein (IGFBP) 4 proteolysis by pregnancy-associated plasma protein-A (PAPP-A) in cells treated with phorbol ester.

Arun S Sivanandam1, Subburaman Mohan, Hirohito Kita, Sanjay Kapur, Shin-Tai Chen, Thomas A Linkhart, Gyorgy Bagi, David J Baylink, Xuezhong Qin.   

Abstract

PAPP-A (pregnancy-associated plasma protein-A) is produced by hSFs (human skin fibroblasts) and hOBs (human osteoblasts) and enhances the mitogenic activity of IGFs (insulin-like growth factors) by degradation of IGFBP-4 (insulin-like growth factor-binding protein 4). PKC (protein kinase C) activation in these cells led to reduction in IGFBP-4 proteolysis. This study was undertaken to determine the mechanism by which activation of PKC suppresses IGFBP-4 proteolysis. Treatment of hSFs/hOBs with TPA (PMA; 100 nM) reduced IGFBP-4 proteolysis without significantly decreasing the PAPP-A level in the CM (conditioned medium). Immunodepletion of the proform of eosinophil major basic protein (proMBP), a known PAPP-A inhibitor, from CM of TPA-treated cells (TPA CM) failed to increase IGFBP-4 proteolytic activity. Transduction of hSFs with proMBP retrovirus increased the concentration of proMBP up to 30 ng/ml and led to a moderate reduction in IGFBP-4 proteolysis. In contrast, TPA treatment blocked IGFBP-4 proteolysis but failed to induce a detectable amount of proMBP in the CM. While proMBP overexpression led to the formation of a covalent proMBP-PAPP-A complex and reduced the migration of PAPP-A on SDS/PAGE, TPA treatment dose- and time-dependently increased the conversion of a approximately 470 kDa PAPP-A form (PAPP-A470) to a approximately 400 kDa PAPP-A form (PAPP-A400). Since unreduced PAPP-A400 co-migrated with the 400 kDa recombinant PAPP-A homodimer and since PAPP-A monomers from reduced PAPP-A470 and PAPP-A400 co-migrated on SDS/PAGE, conversion of PAPP-A470 to PAPP-A400 is unlikely to be caused by proteolytic cleavage of PAPP-A. Consistent with the data showing that the increase in the ratio of PAPP-A400/PAPP-A470 is correlated with the extent of reduction in IGFBP-4 proteolysis, partially purified PAPP-A400 exhibited a 4-fold reduction in IGFBP-4 proteolytic activity compared with PAPP-A470. These data suggest that a novel mechanism, namely conversion of PAPP-A470 to the less-active PAPP-A400, could account for the TPA-induced suppression of PAPP-A activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705967      PMCID: PMC1224057          DOI: 10.1042/BJ20030937

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

Review 1.  The insulin-like growth factor-binding protein (IGFBP) superfamily.

Authors:  V Hwa; Y Oh; R G Rosenfeld
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

Review 2.  Genetics, chemistry, and function of the IGF/IGFBP system.

Authors:  P F Collett-Solberg; P Cohen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.633

Review 3.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.

Authors:  R C Baxter
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-06       Impact factor: 4.310

4.  Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro.

Authors:  D Byun; S Mohan; M Yoo; C Sexton; D J Baylink; X Qin
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

5.  Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4.

Authors:  H Peng; S T Chen; J E Wergedal; J M Polo; J K Yee; K H Lau; D J Baylink
Journal:  Mol Ther       Date:  2001-08       Impact factor: 11.454

Review 6.  IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms.

Authors:  S Mohan; D J Baylink
Journal:  J Endocrinol       Date:  2002-10       Impact factor: 4.286

7.  Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin.

Authors:  H B Boldt; M T Overgaard; L S Laursen; K Weyer; L Sottrup-Jensen; C Oxvig
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

8.  Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor.

Authors:  M T Overgaard; J Haaning; H B Boldt; I M Olsen; L S Laursen; M Christiansen; G J Gleich; L Sottrup-Jensen; C A Conover; C Oxvig
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

9.  Molecular regulation of the IGF-binding protein-4 protease system in human fibroblasts: identification of a novel inducible inhibitor.

Authors:  Bing-Kun Chen; Michael T Overgaard; Laurie K Bale; Zachary T Resch; Michael Christiansen; Claus Oxvig; Cheryl A Conover
Journal:  Endocrinology       Date:  2002-04       Impact factor: 4.736

10.  Differential regulation of pregnancy associated plasma protein (PAPP)-A during pregnancy in human and mouse.

Authors:  Xuezhong Qin; Christopher Sexton; Dongwon Byun; Donna D Strong; David J Baylink; Subburaman Mohan
Journal:  Growth Horm IGF Res       Date:  2002-10       Impact factor: 2.372

View more
  2 in total

1.  Pregnancy-associated plasma protein-A regulates myoblast proliferation and differentiation through an insulin-like growth factor-dependent mechanism.

Authors:  Ashok Kumar; Subburaman Mohan; Jacqueline Newton; Mark Rehage; Kiet Tran; David J Baylink; Xuezhong Qin
Journal:  J Biol Chem       Date:  2005-08-22       Impact factor: 5.157

2.  Can pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?

Authors:  Mualla Polat; Guler Bugdayci; Asli Sahin; Hatice Kaya; Tuna Sezer; Serkan Ozturk
Journal:  Postepy Dermatol Alergol       Date:  2016-10-21       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.